Available to mentor
My career is dedicated to reducing cancer’s burden on patients through translational research and collaborative clinical trials. My clinical and research interests are primarily in head and neck cancer and early-stage therapeutics. These interests stem from the remarkable heterogeneity tumor biology and patient outcomes within a single disease entity, paired with often ineffective therapeutics. My research has focused on development of novel therapeutics for advanced head and neck cancer, biomarker development, and treatment de-escalation strategies in patients with low-risk human papillomavirus related oropharyngeal cancer. My career began by studying small molecule inhibitors in metastatic head and neck cancer which led to development of numerous funded multi-institution investigator initiated clinical trials as a PI. Development of these trials has equipped me with the necessary administrative skills needed for collaborative science including multi-institutional communication, budgeting, and regulatory management. I am the PI of a pivotal multisite investigator-initiated registration trial evaluating MDM-2 inhibition in metastatic salivary gland cancer as well as a co-PI of the NCI iMATCH Feasibility Study S2101 investigating biomarker stratified treatment of advanced solid tumors. Given my research experience, involvement with the head and neck community, and translational research I was appointed to the NCI Recurrent/Metastatic Head and Neck Task Force. In the Spring of 2020, I was also appointed as Co-Director of the University of Michigan Experimental Therapeutics/Phase 1 Program.
-
Center MemberRogel Cancer Center
1) Novel therapeutics and treatment strategies for advanced / metastatic diseases including head and neck cancer.
2) Biomarker development in head and neck squamous cell carcinoma.
3) Tumor immune microenvironment modulation in advanced head and neck cancer.
-
Margalit DN, Anker CJ, Aristophanous M, Awan M, Bajaj GK, Bradfield L, Califano J, Caudell JJ, Chapman CH, Garden AS, Harari PM, Helms A, Lin A, Maghami E, Mehra R, Parker L, Shnayder Y, Spencer S, Swiecicki PL, Tsai JC, Sher DJ. Pract Radiat Oncol, 2024 Jun 18;Journal ArticleRadiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.
DOI:10.1016/j.prro.2024.05.007 PMID: 39078350 -
Benjamin WJ, Feng AL, Heft Neal M, Bellile E, Casper KA, Malloy KM, Rosko AJ, Stucken CL, Prince ME, Mierzwa ML, Taylor JMG, Eisbruch A, Spector ME, Wolf GT, Swiecicki PL, Worden FP, Chinn SB. Oral Oncol, 2024 Sep; 156: 106917Journal ArticleUtility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
DOI:10.1016/j.oraloncology.2024.106917 PMID: 38945011 -
Honma Y, Swiecicki PL, Rosenberg AJ, Hanna GJ, Yang Bruce J, Fujisawa T, Muro K, Kaplan JB, Gorla SR, Liu S, Meng C, Geiger JL. Journal of Clinical Oncology, 2024 Aug 10; 42 (23_suppl): tps148 - tps148.Journal ArticleEnfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.
DOI:10.1200/jco.2024.42.23_suppl.tps148 -
Swiecicki P. 2024 Jul 1;PresentationBest of ASCO sponsored by Binyatara Foundation
-
Lakhani NJ, Hamid O, Brana I, Lostes-Bardaji MJ, Gajate P, Lopez-Criado MP, Swiecicki P, de Miguel MJ, Gil-Martin M, Moreno V, Soyano Muller AE, Gonzalez Ortiz A, Sun D, Modi D, Zheng W, Jankovic V, Salvati M, Fury MG, Cristea MC. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 2650 - 2650.Journal ArticleA phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.
DOI:10.1200/jco.2024.42.16_suppl.2650 -
Gaillard S, Starodub A, O'Neil B, Mathews CA, Dumbrava EE, Friedman CF, Swiecicki P, Oh C, Andreu C, Lee L, Campbell J, Bowler TG, Drutman S, LoRusso P. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): tps3181 - tps3181.Journal ArticleA phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.
DOI:10.1200/jco.2024.42.16_suppl.tps3181 -
Swiecicki P. 2024 Jun 1;PresentationASCO Mini oral abstract session
-
Dermody S, Brummel C, Brenner C, Casper K, Chinn SB, Malloy KM, Mierzwa ML, Neal MH, Prince M, Shah JL, Shuman A, Stucken C, Spector M, Worden FP, Swiecicki P. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 6102 - 6102.Journal ArticleClinical outcomes in salivary adenoid cystic carcinoma.
DOI:10.1200/jco.2024.42.16_suppl.6102